Invest in the Future of Cancer Therapy
A Groundbreaking Pre-IPO Investment Opportunity
At Jabez Biosciences, we are pioneering the future of cancer treatment with breakthrough small molecule therapeutics. Our flagship drug, JBZ-001, is a powerful DHODH inhibitor designed to disrupt cancer’s ability to grow while enhancing the effectiveness of immunotherapy and chemotherapy.
With a team of industry veterans and a clear clinical roadmap, we are advancing toward major milestones—and you have the opportunity to invest before we go public.
Why Invest in Jabez Biosciences Now?
✅ Pre-IPO Growth Potential – This is an exclusive early-stage investment opportunity in an emerging biotech company before it reaches the public markets.
✅ Breakthrough Science – Our targeted small molecule approach disrupts cancer’s nucleotide supply chain, without affecting healthy cells.
✅ Combination Therapy Advantage – JBZ-001 synergizes with immunotherapy and chemotherapy, and other small molecules significantly improving patient outcomes.
✅ High-Growth Market – The oncology therapeutics market is projected to exceed $250 billion by 2030, creating significant investment potential.
✅ Experienced Leadership – Our team consists of industry pioneers with decades of experience in cancer research, drug development, and biotech innovation.
✅ Regulation A+ Offering – This pre-IPO investment opportunity allows both accredited and non-accredited investors to participate before a potential IPO or major liquidity event.
Lead Investors In Jabez
Jabez Biosciences is proud to have the support of MedTek and J. Bradley Hilton with the Hilton Finance, LLC who have both made strategic investments in the company.
“Jabez Biosciences represents the kind of groundbreaking innovation that drives long-term success. Their approach to cancer treatment is not only revolutionary but also deeply needed in today’s medical landscape. As an investor, I look for companies that combine world-class leadership, cutting-edge science, and strong business fundamentals—and Jabez delivers on all fronts. Investing in Jabez Biosciences is more than just an opportunity for strong financial returns—it’s a chance to be part of a movement that will change lives. The Hilton Family Office is proud to support Jabez, and we believe in their vision for the future of cancer care.”
“In the rapidly evolving field of biotechnology, true breakthroughs are rare. When I discovered Jabez Biosciences and their pioneering work in cancer therapeutics, I knew this was a company poised to make a real difference. Their flagship therapy, JBZ-001, represents a major step forward in targeted cancer treatment—offering hope to patients while addressing a massive market need. Beyond their cutting-edge science, Jabez Biosciences is led by a world-class team with the vision, expertise, and determination to bring innovative treatments to market. As an investor, I look for companies that combine scientific innovation with strong business fundamentals, and Jabez delivers on both fronts. I’m proud to support Jabez Biosciences and their mission to revolutionize cancer care. This investment isn’t just about financial returns—it’s about backing a company that is set to transform lives.”
Investment Structure & Offering Details
- Offering Type: Regulation A+ Tier II
- Investment Minimum: $5,000
- Share Price: $2.00 per share
- Offering Size: $10,000,000
- Investor Eligibility: Open to both accredited and non-accredited investors
- Use of Funds: Clinical trials, research & development, regulatory approvals, and market expansion
What People Are Saying About Jabez
Frequently Asked Questions (FAQ)
Who can invest in Jabez Biosciences?
Through our Regulation A+ offering, both accredited and non-accredited investors can participate in this pre-IPO investment opportunity.
How will my investment be used?
Funds raised will be used to advance JBZ-001 through clinical trials, expand research and development, secure regulatory approvals, and prepare for commercialization.
What is the exit strategy for investors?
We are actively building toward a potential IPO or strategic acquisition that could create a liquidity event for investors.
Why is JBZ-001 different from existing cancer treatments?
JBZ-001 is a small molecule DHODH inhibitor that shuts down cancer’s nucleotide supply chain, enhancing existing therapies while maintaining a strong safety profile.
How do I invest?
Click the "Get Started" button below to start your investment in Jabez Biosciences today.
Be Part of the Future of Cancer Therapy
This Is Your Opportunity to Invest in Cutting-Edge Cancer Treatment
The time to invest in Jabez Biosciences is now! With JBZ-001 poised to transform cancer therapy, you have the chance to be part of a revolutionary breakthrough before we go public.
Exclusive Pre-IPO Opportunity – Invest before a major liquidity event.
Strong Market Potential – A high-growth industry projected to exceed $250 billion.
A Mission That Matters – Back a company committed to saving lives and reshaping cancer care.
Get Started Now
Click the ‘Get Started’ button to receive our full investment package, offering details, and next steps for securing your place in this groundbreaking opportunity.
Legal Disclaimers
Forward-Looking Statements: This website and its materials may contain forward-looking statements regarding future events, projections, and business strategies. These statements are subject to significant risks and uncertainties and should not be relied upon as guarantees of future performance.
Investment Risk: Investing in early-stage biotech companies involves risk, including the potential loss of principal. There is no guarantee of an IPO, liquidity event, or return on investment. Please consult with a financial advisor before making any investment decisions.
SEC Qualification: This Regulation A+ offering is made pursuant to an offering statement that has been qualified by the U.S. Securities and Exchange Commission (SEC). However, the SEC has not approved or endorsed the merits of this offering. Potential investors should review all offering materials carefully before investing.
No Offer or Solicitation: This webpage does not constitute an offer to sell, or a solicitation of an offer to buy, any securities. The offering is made solely through the official offering circular available at Jabezbio.com